Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

Oxygen therapy is a treatment going back to the days of Ben Franklin. In 1783, a French physician was the first to use it, ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Analysts are estimating that Liquidia will report an earnings per share (EPS) of $-0.41. The market awaits Liquidia's announcement, with hopes high for news of surpassing estimates and providing ...

Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2025, totaled approximately $408.2 million VYGLXIA NDA for spinocerebellar ataxia ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...